drugset / Trial / NCT00634348

A Study Comparing the Efficacy and Safety of Ziprasidone and Aripiprazole for the Treatment fo Schizophrenia or Schizoaffective Disorder in Hospitalized Patients

NCT00634348

Phase 4 Completed 256 enrolled Viatris Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to compare the efficacy and safety of ziprasidone and aripiprazole in hospitalized patients with schizophrenia or schizoaffective disorder

Timeline

Start
2004-04
Primary completion
Completion
2005-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aripiprazole Other / unclassified 10 mg Oral
Comparator Aripiprazole Other / unclassified 15 mg Oral
Comparator Aripiprazole Other / unclassified 30 mg Oral
Comparator Ziprasidone Small molecule 40 mg Oral
Comparator Ziprasidone Small molecule 60 mg Oral
Comparator Ziprasidone Small molecule 80 mg Oral

Indications